Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Blueprint Medicines Corp (BPMC) Going to Burn These Hedge Funds?

Page 1 of 2

Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors’ favor when it comes to beating the market, as evidenced by the fact that less than 49% of the stocks in the S&P 500 did so during the 12-month period ending October 30. However, 63% of hedge funds’ top 30 stock picks from the index did beat the market, and returned nearly twice as much on average as the index. Thus, we can see that the tireless research and efforts of hedge funds to identify winning stocks can work to our advantage when we know how to use the data. While not all of their picks will be winners, our odds are much better following their best stock picks than trying to go it alone.

Hedge fund interest in Blueprint Medicines Corp (NASDAQ:BPMC) shares was flat at the end of last quarter. This is usually a negative indicator. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Silver Bay Realty Trust Corp (NYSE:SBY), MakeMyTrip Limited (NASDAQ:MMYT), and Universal American Corporation (NYSE:UAM) to gather more data points.

Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Trade (NASDAQ:BPMC) Now!

According to most market participants, hedge funds are perceived as unimportant, old financial vehicles of yesteryear. While there are more than 8000 funds with their doors open at the moment, We look at the aristocrats of this club, approximately 700 funds. These hedge fund managers orchestrate the lion’s share of the hedge fund industry’s total capital, and by tracking their first-class stock picks, Insider Monkey has unsheathed a number of investment strategies that have historically outrun the broader indices. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Keeping this in mind, we’re going to view the latest action regarding Blueprint Medicines Corp (NASDAQ:BPMC).

How have hedgies been trading Blueprint Medicines Corp (NASDAQ:BPMC)?

Heading into Q4, a total of 14 of the hedge funds tracked by Insider Monkey were long this stock, a change of 0% from one quarter earlier. With the smart money’s sentiment swirling, there exists a select group of key hedge fund managers who were upping their stakes substantially (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Mark Lampert’s Biotechnology Value Fund / BVF Inc has the largest position in Blueprint Medicines Corp (NASDAQ:BPMC), worth close to $36.3 million, amounting to 7.3% of its total 13F portfolio. On Biotechnology Value Fund / BVF Inc’s heels is Jacob Gottlieb of Visium Asset Management, with an $21.8 million position; the fund has 0.3% of its 13F portfolio invested in the stock. Some other members of the smart money that are bullish consist of Christopher James’s Partner Fund Management, Peter Kolchinsky’s RA Capital Management and Richard Driehaus’s Driehaus Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!